The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial

Journal of Infection

Volumn 67, Issue 4, 2013, Pages 313-321

  Chapplain, Jean Marc ^a   Bellissant, Eric ^a   Guyader, Dominique ^a   Molina, Jean Michel ^b   Poizot Martin, Isabelle ^c   Perré, Philippe ^d   Pialoux, Gilles ^e   Turlin, Bruno ^a   Mouchel, Catherine ^a   Renault, Alain ^a   Michelet, Christian ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c AIX MARSEILLE UNIV   (France)

^d La Roche/Yon Hospital ^*  (France)

^e HÔPITAL TENON   (France)

Author keywords

HIV HCV co infection; Liver fibrosis; Metavir fibrosis score; Peg interferon; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METAVIR FIBROSIS SCORE; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 84882856658     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.05.007     Document Type: Article

References (25)

1. Hogg R.S., Heath K.V., Yip B., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998, 279:450-454.
2. Ray M., Logan R., Sterne J.A., Hernádez-Díaz S., Robins J.M., Sabin C., et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010, 24:123-137. HIV-CAUSAL Collaboration.
3. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50:1387-1396. Antiretroviral Therapy Cohort Collaboration.
4. Weber R., Sabin C.A., Friis-Møller N., Reiss P., El-Sadr W.M., Kirk O., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the DAD Study. Arch Intern Med 2006, 166:1632-1641.
5. Tedaldi E.M., Baker R.K., Moorman A.C., Alzola C.F., Furhrer J., McCabe R.E., et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003, 36:363-367.
6. Lewden C., May T., Rosenthal E., Burty C., Bonnet F., Costagliola D., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008, 48:590-598.
7. Salmon-Ceron D., Rosenthal E., Lewden C., Bouteloup V., May T., Burty C., et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national mortalité 2005 study. J Hepatol 2009, 50:736-745.
8. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc 2004, 292:2839-2848. RIBAVIC Study Team.
9. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-García J., Lazzarin A., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
10. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
11. Imazeki F., Yokosuka O., Fukai K., Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003, 38:493-502.
12. Yoshida H., Arakawa Y., Sata M., Nishiguchi S., Yano M., Fujiyama S., et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123:483-491.
13. Kasahara A., Tanaka H., Okanoue T., Imai Y., Tsubouchi H., Yoshioka K., et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004, 11:148-156.
14. Rodríguez-Torres M., Rodríguez-Orengo J.F., Ríos-Bedoya C.F., Fernández-Carbia A., González-Lassalle E., Salgado-Mercado R., et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007, 38:32-38.
15. Moreno-Monteagudo J.A., Castro A., De Pedro A., Lorenzo J.A., Fernández-Bermejo M., Lopez S., et al. Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. Aliment Pharmacol Ther 2002 Feb, 16(2):243-249.
16. Chevallier M., Guerret S., Chossegros P., Gerard F., Grimaud J.A. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994, 20:349-355.
17. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164-1172.
18. Di Bisceglie A.M., Shiffman M.L., Everson G.T., Lindsay K.L., Everhart J.E., Wright E.C., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-2441.
19. Bruix J., Poynard T., Colombo M., Schiff E., Reichen J., Burak K., et al. PegIntron maintenance therapy in cirrhotic (METAVIR F4) HCV patients, who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial [Abstract]. J Hepatol 2009, 50:S22.
20. Afdhal N.H., Levine R., Brown R., Freilich B., O'Brien M., Brass C. Colchicine versus PEGinterferon alfa-2b long-term therapy: results of the 4-year copilot trial [Abstract]. J Hepatol 2008, 48:S4.
21. Sherman K.E., Andersen J.W., Butt A.A., Umbleja T., Alston B., Koziel M.J., et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010, 55:597-605.
22. Dienstag J.L. The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36:S152-S160.
23. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
24. Pockros P.J., Hamzeh F.M., Martin P., Lentz E., Zhou X., Govindarajan S., et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 2010, 52:1193-1200.
25. Lissen E., Clumeck N., Sola R., Mendes-Correa M., Montaner J., Nelson M., et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006, 20:2175-2181.